TELA Bio, Inc. cash flow to debt ratio of -50.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

TELA Bio, Inc.'s free cash flow has increased -32.68% from $-42.58M last year to $-28.67M, signaling increasing performance

TELA Bio, Inc.'s debt to equity ratio is -10.84, signaling that the company spent its equity and risk bankruptcy.

TELA Bio, Inc.'s debt to equity ratio is -10.84, signaling that the company spent its equity and risk bankruptcy.

TELA Bio, Inc. has negative EBITDA, making leverage ratio unreliable

TELA Bio, Inc.'s interest coverage ratio is -17.14, which means that the company struggles to meet interest obligations, signaling financial risk.

TELA Bio, Inc.'s profit margin has increased (-9.72%) in the last year from -54.60% to -49.30%, signaling increasing performance

TELA Bio, Inc.'s short-term assets of $75.58M exceed its short-term liabilities of $17.98M

TELA Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TELA Bio, Inc.'s return on equity of -1.34K%, is lower than 15.00%, indicating bad performance

TELA Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TELA Bio, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

TELA Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TELA Bio, Inc. has negative free cash flow, indicating cash burn

TELA Bio, Inc.'s yearly earnings has decreased 2.62% since last year from $-37.84M to $-38.83M, signaling decreasing performance

TELA Bio, Inc.'s yearly revenue has increased 15.84% since last year from $69.30M to $80.28M, signaling increasing performance

ROIC -64.29% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TELA Bio, Inc.'s 3-year revenue CAGR of 24.68% is positive, indicating growing revenue over the past 3 years

TELA Bio, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

TELA Bio, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

TELA Bio, Inc. has insufficient data to evaluate this check.

TELA Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TELA Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

TELA Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TELA Bio, Inc. is overvalued relative to its fair value price of -24.95 based on Earnings Fair Value model

TELA Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TELA Bio, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

TELA Bio, Inc. has a price-to-sales ratio of 0.53x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue